Login to Your Account



CureDM's Islet-Growing Drug Lands $335M Sanofi Alliance

By Jennifer Boggs


Friday, April 9, 2010
Small biotech CureDM LLC's approach to treating diabetes by stimulating the body's production of insulin-producing islet cells might be months away from the clinic, but it's already sparked the interest of big pharma, landing the firm a potential $335 million deal with Sanofi-Aventis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription